Cytokinetics (CYTK) Financials

$38.56 -0.92 (-2.34%)

As of 10:14 AM Eastern

Annual Income Statements for Cytokinetics

This table shows Cytokinetics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Net Income / (Loss) Attributable to Common Shareholders	-38	16	-128	-106	-122	-127	-215	-389	-526	-590
Consolidated Net Income / (Loss)	-38	16	-128	-106	-122	-127	-215	-389	-526	-590
Net Income / (Loss) Continuing Operations	-38	16	-128	-106	-122	-127	-215	-389	-526	-590
Total Pre-Tax Income	-38	16	-128	-106	-122	-133	-216	-400	-554	-641
Total Operating Income	-37	19	-113	-89	-99	-94	-186	-324	-496	-536
Total Gross Profit	29	106	13	32	27	56	70	95	7.53	18
Total Revenue	29	106	13	32	27	56	70	95	7.53	18
Operating Revenue	-	-	13	32	27	56	70	95	7.53	18
Total Cost of Revenue	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Operating Expenses	66	88	127	120	126	150	257	419	504	555
Selling, General & Admin Expense	20	28	36	31	40	53	97	178	174	215
Research & Development Expense	46	60	90	89	86	97	160	241	330	339
Total Other Income / (Expense), net	-0.09	-2.23	-14	-17	-23	-39	-29	-76	-58	-105
Interest Expense	0.27	2.70	17	22	27	39	29	51	58	87
Other Income / (Expense), net	0.17	0.46	2.60	4.35	4.54	0.00	0.00	-25	0.00	-18
Other Gains / (Losses), net	-	-	-	-	-	5.33	0.33	11	28	52
Basic Earnings per Share	($0.97)	$0.41	($2.59)	($1.95)	($2.11)	($1.97)	($2.80)	($4.33)	($5.45)	($5.26)
Weighted Average Basic Shares Outstanding	38.81M	39.94M	49.40M	54.42M	57.58M	64.52M	76.89M	89.83M	96.52M	111.98M
Diluted Earnings per Share	($0.97)	$0.39	($2.59)	($1.95)	($2.11)	($1.97)	($2.80)	($4.33)	($5.45)	($5.26)
Weighted Average Diluted Shares Outstanding	38.81M	42.56M	49.40M	54.42M	57.58M	64.52M	76.89M	89.83M	96.52M	111.98M
Weighted Average Basic & Diluted Shares Outstanding	38.70M	41.73M	49.40M	54.42M	57.58M	64.52M	76.89M	95.16M	103.00M	118.41M

This table shows Cytokinetics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Net Income / (Loss) Attributable to Common Shareholders	-142	-137	-131	-128	-129	-138	-136	-144	-161	-150
Consolidated Net Income / (Loss)	-142	-137	-131	-129	-129	-137	-136	-143	-161	-150
Net Income / (Loss) Continuing Operations	-142	-137	-131	-129	-129	-137	-136	-144	-161	-150
Total Pre-Tax Income	-142	-147	-138	-129	-129	-158	-144	-144	-178	-176
Total Operating Income	-108	-127	-124	-122	-122	-127	-126	-130	-141	-139
Total Gross Profit	2.52	1.96	4.61	0.87	0.38	1.67	0.84	0.25	0.46	17
Total Revenue	2.52	1.96	4.61	0.87	0.38	1.67	0.84	0.25	0.46	17
Operating Revenue	2.52	1.96	4.61	0.87	0.38	1.67	0.84	0.25	0.46	17
Total Operating Expenses	111	129	129	123	123	129	127	130	141	156
Selling, General & Admin Expense	48	54	50	40	40	44	46	51	57	62
Research & Development Expense	63	75	79	83	83	85	82	80	85	94
Total Other Income / (Expense), net	-34	-20	-13	-6.59	-7.16	-31	-17	-13	-37	-37
Interest Expense	16	16	13	13	14	17	17	24	22	23
Other Income / (Expense), net	-18	-	0.00	6.78	6.84	-14	0.00	11	-15	-15
Basic Earnings per Share	($1.52)	($1.53)	($1.38)	($1.34)	($1.35)	($1.38)	($1.33)	($1.31)	($1.36)	($1.26)
Weighted Average Basic Shares Outstanding	93.76M	89.83M	95.16M	95.76M	96.07M	96.52M	101.92M	109.24M	117.69M	111.98M
Diluted Earnings per Share	($1.52)	($1.53)	($1.38)	($1.34)	($1.35)	($1.38)	($1.33)	($1.31)	($1.36)	($1.26)
Weighted Average Diluted Shares Outstanding	93.76M	89.83M	95.16M	95.76M	96.07M	96.52M	101.92M	109.24M	117.69M	111.98M
Weighted Average Basic & Diluted Shares Outstanding	94.63M	95.16M	95.64M	96.00M	98.05M	103.00M	104.85M	117.66M	118.01M	118.41M

This table details how cash moves in and out of Cytokinetics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Net Change in Cash & Equivalents	45	1.80	58	-83	-5.82	47	30	-45	46	-18
Net Cash From Operating Activities	4.88	37	-102	-101	-91	8.94	-143	-300	-414	-396
Net Cash From Continuing Operating Activities	4.88	37	-102	-101	-91	8.94	-143	-300	-414	-396
Net Income / (Loss) Continuing Operations	-38	16	-128	-106	-122	-127	-215	-389	-526	-590
Consolidated Net Income / (Loss)	-38	16	-128	-106	-122	-127	-215	-389	-526	-590
Depreciation Expense	0.59	0.74	1.92	1.24	1.29	1.83	2.28	5.81	12	9.53
Amortization Expense	-	-	0.00	-1.68	-2.59	-1.19	4.89	-4.71	-16	-33
Non-Cash Adjustments To Reconcile Net Income	4.55	7.66	24	35	41	51	57	115	111	174
Changes in Operating Assets and Liabilities, net	37	12	0.49	-30	-8.44	85	8.46	-26	4.50	43
Net Cash From Investing Activities	16	-52	-66	5.13	-75	-197	-148	-262	239	-553
Net Cash From Continuing Investing Activities	16	-52	-66	5.13	-75	-197	-148	-262	239	-553
Purchase of Property, Plant & Equipment	-0.56	-1.60	-2.88	-0.89	-2.62	-11	-49	-11	-1.42	-3.91
Purchase of Investments	-116	-145	-240	-240	-278	-436	-525	-855	-635	-1,293
Sale and/or Maturity of Investments	132	95	177	246	206	250	426	605	876	744
Net Cash From Financing Activities	24	17	226	13	160	234	320	516	221	931
Net Cash From Continuing Financing Activities	24	17	226	13	160	234	320	516	221	931
Repayment of Debt	-	-	-	0.00	134	0.00	0.00	-191	-0.86	-9.62
Issuance of Debt	15	17	16	9.90	1.71	0.00	0.00	673	50	200
Issuance of Common Equity	8.67	0.00	120	3.23	38	234	324	18	183	760
Other Financing Activities, net	0.00	0.00	91	0.00	-13	-0.10	-4.45	17	-11	-20
Other Net Changes in Cash	-	-	-	-	-	-	-	0.00	-0.02	0.21
Cash Interest Paid	0.09	1.90	2.13	2.88	4.06	9.62	9.18	15	10	26

This table details how cash moves in and out of Cytokinetics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Net Change in Cash & Equivalents	13	-39	36	-34	31	13	6.95	70	-143	48
Net Cash From Operating Activities	-84	-98	-122	-122	-96	-74	-130	-99	-102	-66
Net Cash From Continuing Operating Activities	-84	-98	-122	-122	-96	-74	-130	-99	-102	-66
Net Income / (Loss) Continuing Operations	-142	-137	-131	-129	-129	-137	-136	-143	-161	-150
Consolidated Net Income / (Loss)	-142	-137	-131	-129	-129	-137	-136	-143	-161	-150
Depreciation Expense	1.41	1.66	1.85	1.86	1.85	6.34	2.33	2.41	2.41	2.38
Amortization Expense	-2.04	-4.22	-3.04	-3.86	-3.74	-5.10	-5.22	-8.50	-11	-7.70
Non-Cash Adjustments To Reconcile Net Income	48	26	29	33	34	15	35	37	61	41
Changes in Operating Assets and Liabilities, net	11	16	-19	-24	1.29	46	-26	13	6.48	49
Net Cash From Investing Activities	-292	29	165	82	73	-81	33	-652	-45	111
Net Cash From Continuing Investing Activities	-292	29	165	82	73	-81	33	-652	-45	111
Purchase of Property, Plant & Equipment	-6.33	-3.21	-0.40	-0.72	-0.22	-0.08	0.00	-1.92	-0.70	-1.29
Purchase of Investments	-467	-125	-90	-202	-118	-226	-143	-815	-214	-121
Sale and/or Maturity of Investments	181	158	256	284	191	145	175	166	170	233
Net Cash From Financing Activities	389	30	-7.18	5.48	54	169	104	821	3.43	2.38
Net Cash From Continuing Financing Activities	389	30	-7.18	5.48	54	169	104	821	3.43	2.38
Repayment of Debt	-141	-0.11	-0.21	-0.21	-0.22	-0.22	-0.93	-2.88	-2.89	-2.91
Issuance of Common Equity	6.19	3.60	3.55	5.69	4.44	169	123	624	6.32	6.48
Other Financing Activities, net	-	26	-11	-	-	-	-18	-	-	-1.18
Other Net Changes in Cash	-	-	0.00	-	-	-0.02	-	-	-0.13	0.29
Cash Interest Paid	0.08	9.61	0.04	9.91	0.03	0.32	10	0.67	14	0.64

This table presents Cytokinetics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Total Assets	115	170	295	211	290	534	841	1,015	824	1,402
Total Current Assets	113	159	274	208	234	474	536	795	628	1,108
Cash & Equivalents	65	67	125	42	36	83	113	66	113	95
Short-Term Investments	46	89	144	156	189	381	359	717	502	981
Accounts Receivable	0.01	0.02	1.11	2.23	5.16	4.42	52	0.15	1.28	17
Prepaid Expenses	1.65	2.36	4.29	2.16	3.48	5.74	12	12	12	15
Plant, Property, & Equipment, net	1.75	3.64	3.57	3.20	4.53	13	73	80	69	66
Total Noncurrent Assets	0.38	7.87	17	0.30	52	46	232	139	128	228
Long-Term Investments	0.18	7.67	17	0.00	43	37	152	47	41	145
Other Noncurrent Operating Assets	0.20	0.20	0.43	0.30	8.88	9.28	80	92	87	83
Total Liabilities & Shareholders' Equity	115	170	295	211	290	534	841	1,015	824	1,402
Total Liabilities	47	76	185	185	301	420	597	1,123	1,211	1,537
Total Current Liabilities	32	33	32	22	26	31	72	85	103	180
Short-Term Debt	0.00	2.50	0.00	2.61	-	2.79	-	0.96	10	12
Accounts Payable	2.24	4.24	5.25	3.76	8.16	8.05	21	26	22	20
Accrued Expenses	8.42	18	17	16	12	19	34	44	43	55
Current Deferred Revenue	21	8.06	9.57	-	-	-	-	-	0.00	52
Other Current Liabilities	0.13	0.42	0.23	0.07	5.74	1.05	16	14	28	40
Total Noncurrent Liabilities	15	43	153	163	275	389	526	1,038	1,108	1,357
Long-Term Debt	15	27	32	40	129	136	143	610	607	646
Other Noncurrent Operating Liabilities	-	0.14	106	123	145	166	296	428	501	712
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	69	94	110	26	-11	113	244	-108	-386	-135
Total Preferred & Common Equity	69	94	110	26	-11	113	244	-108	-386	-135
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	69	94	110	26	-11	113	244	-108	-386	-135
Common Stock	603	613	756	769	853	1,106	1,452	1,482	1,726	2,564
Retained Earnings	-535	-518	-646	-743	-865	-992	-1,208	-1,586	-2,112	-2,702
Accumulated Other Comprehensive Income / (Loss)	0.15	0.14	0.34	0.50	0.68	0.15	-0.87	-3.59	-0.01	2.40

This table presents Cytokinetics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024
Total Assets	1,076	890	780	741	808	1,524	1,436
Total Current Assets	884	681	587	561	639	1,068	1,019
Cash & Equivalents	106	102	69	100	120	190	47
Short-Term Investments	761	562	497	440	499	867	965
Accounts Receivable	2.29	1.01	0.99	2.50	0.83	0.00	0.24
Prepaid Expenses	14	16	20	20	19	11	6.67
Plant, Property, & Equipment, net	80	79	77	76	68	66	64
Total Noncurrent Assets	111	130	116	104	101	390	353
Long-Term Investments	29	40	27	15	15	305	269
Other Noncurrent Operating Assets	83	90	89	88	86	85	84
Total Liabilities & Shareholders' Equity	1,076	890	780	741	808	1,524	1,436
Total Liabilities	1,092	1,119	1,113	1,179	1,204	1,415	1,450
Total Current Liabilities	76	75	66	78	89	103	110
Short-Term Debt	-	-	-	-	12	12	12
Accounts Payable	14	17	13	14	13	9.47	12
Accrued Expenses	40	36	31	33	40	40	50
Other Current Liabilities	22	22	22	31	24	42	37
Total Noncurrent Liabilities	1,015	1,044	1,047	1,102	1,115	1,312	1,340
Long-Term Debt	609	611	610	609	607	643	644
Other Noncurrent Operating Liabilities	407	433	438	493	509	669	696
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	-16	-229	-333	-439	-396	109	-14
Total Preferred & Common Equity	-16	-229	-333	-439	-396	109	-14
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	-16	-229	-333	-439	-396	109	-14
Common Stock	1,438	1,490	1,514	1,537	1,852	2,501	2,532
Retained Earnings	-1,449	-1,717	-1,846	-1,975	-2,248	-2,391	-2,552
Accumulated Other Comprehensive Income / (Loss)	-5.56	-1.65	-1.46	-0.87	-0.54	-1.02	5.39

This table displays calculated financial ratios and metrics derived from Cytokinetics' official financial filings.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	-38.95%	271.30%	-87.44%	135.64%	-14.71%	107.79%	26.15%	34.30%	-92.04%	145.34%
EBITDA Growth	-158.86%	154.28%	-647.33%	21.92%	-12.49%	2.43%	-92.00%	-94.28%	-43.68%	-15.50%
EBIT Growth	-154.22%	151.44%	-678.53%	23.67%	-11.55%	0.41%	-98.33%	-87.39%	-42.12%	-11.76%
NOPAT Growth	-153.54%	171.37%	-524.77%	21.59%	-11.19%	4.98%	-98.33%	-74.01%	-53.05%	-8.07%
Net Income Growth	-156.05%	143.87%	-876.70%	16.83%	-14.49%	-4.60%	-69.15%	-80.65%	-35.30%	-12.03%
EPS Growth	-136.59%	140.21%	-764.10%	24.71%	-8.21%	6.64%	-42.13%	-54.64%	-25.87%	3.49%
Operating Cash Flow Growth	110.89%	657.36%	-375.16%	0.53%	10.18%	109.84%	-1,693.67%	-110.15%	-38.33%	4.45%
Free Cash Flow Firm Growth	124.57%	171.43%	-17.48%	-405.85%	33.71%	166.78%	-524.37%	3.38%	-81.86%	59.84%
Invested Capital Growth	-421.32%	-39.75%	-262.38%	9.32%	-14.62%	-66.41%	4.71%	-37.82%	-29.89%	-64.85%
Revenue Q/Q Growth	-29.52%	28.16%	-71.27%	42.50%	-13.42%	2.78%	226.81%	-36.19%	-3.65%	473.90%
EBITDA Q/Q Growth	-90.32%	565.95%	-60.94%	17.51%	-1.95%	-22.15%	8.77%	-63.38%	0.68%	-3.46%
EBIT Q/Q Growth	-87.77%	725.83%	-60.15%	18.67%	-2.14%	-22.43%	7.31%	-59.52%	-0.08%	-2.35%
NOPAT Q/Q Growth	-87.36%	844.26%	-63.91%	14.49%	-2.33%	-15.63%	7.31%	-48.12%	-0.08%	-2.22%
Net Income Q/Q Growth	-89.12%	24,456.72%	-59.44%	11.65%	-3.55%	-11.66%	5.84%	-37.86%	0.09%	-2.28%
EPS Q/Q Growth	-90.20%	657.14%	-61.88%	12.95%	-1.44%	-3.68%	8.20%	-38.34%	2.68%	2.23%
Operating Cash Flow Q/Q Growth	-27.07%	172.82%	-72,269.50%	10.40%	-7.99%	114.36%	-212.31%	-21.72%	5.51%	2.09%
Free Cash Flow Firm Q/Q Growth	40.85%	152.75%	-77.62%	13.31%	-17.11%	210.09%	-384.11%	-6.86%	6.20%	11.24%
Invested Capital Q/Q Growth	7.47%	-241.10%	-9.92%	-12.08%	-5.88%	-48.39%	15.04%	-7.56%	-10.34%	-9.48%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
EBITDA Margin	-127.87%	18.69%	-814.44%	-269.85%	-355.91%	-167.13%	-254.36%	-367.95%	-6,640.74%	-3,126.19%
Operating Margin	-130.53%	17.56%	-848.26%	-282.26%	-367.97%	-168.27%	-264.54%	-342.75%	-6,589.71%	-2,902.72%
EBIT Margin	-129.92%	18.00%	-828.80%	-268.46%	-351.09%	-168.27%	-264.54%	-369.12%	-6,589.71%	-3,001.78%
Profit (Net Income) Margin	-130.86%	15.46%	-955.94%	-337.41%	-452.93%	-228.00%	-305.72%	-411.21%	-6,988.63%	-3,191.11%
Tax Burden Percent	100.00%	100.00%	100.00%	100.15%	100.00%	95.98%	99.85%	97.17%	95.01%	91.96%
Interest Burden Percent	100.72%	85.91%	115.34%	125.50%	129.00%	141.17%	115.74%	114.65%	111.62%	115.60%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Equity (ROE)	-46.69%	20.19%	-125.16%	-156.57%	-1,622.88%	-248.50%	-120.54%	-572.15%	212.96%	226.00%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	-30.00%	13.42%	-47.66%	-33.43%	-37.66%	-22.81%	-27.10%	-37.62%	-53.96%	-49.82%
Return on Assets (ROA)	-30.22%	11.53%	-54.97%	-42.01%	-48.58%	-30.91%	-31.32%	-41.91%	-57.23%	-52.97%
Return on Common Equity (ROCE)	-46.69%	20.19%	-125.16%	-156.57%	-1,622.88%	-248.50%	-120.54%	-572.15%	212.96%	226.00%
Return on Equity Simple (ROE_SIMPLE)	-54.67%	17.44%	-116.34%	-409.84%	1,112.66%	-112.27%	-88.29%	360.48%	136.22%	435.49%
Net Operating Profit after Tax (NOPAT)	-26	19	-79	-62	-69	-66	-130	-227	-347	-375
NOPAT Margin	-91.37%	17.56%	-593.79%	-197.58%	-257.58%	-117.79%	-185.18%	-239.93%	-4,612.80%	-2,031.90%
Net Nonoperating Expense Percent (NNEP)	-12.56%	-1.93%	-24.98%	-21.49%	-35.60%	-24.58%	-20.14%	-46.32%	-139.43%	-71.16%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	-	-	-45.15%	-150.28%	-71.95%
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	68.63%	26.15%	272.80%	99.30%	147.42%	94.61%	137.45%	188.16%	2,305.60%	1,165.50%
R&D to Revenue	161.90%	56.29%	675.46%	282.96%	320.55%	173.66%	227.09%	254.59%	4,384.10%	1,837.22%
Operating Expenses to Revenue	230.53%	82.44%	948.26%	382.26%	467.97%	268.27%	364.54%	442.75%	6,689.71%	3,002.72%
Earnings before Interest and Taxes (EBIT)	-37	19	-111	-85	-94	-94	-186	-349	-496	-555
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-37	20	-109	-85	-96	-93	-179	-348	-500	-578
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	5.92	5.22	4.00	13.33	0.00	12.97	15.68	0.00	0.00	0.00
Price to Tangible Book Value (P/TBV)	5.92	5.22	4.00	13.33	0.00	12.97	15.68	0.00	0.00	0.00
Price to Revenue (P/Rev)	14.18	4.63	32.85	10.98	23.33	26.35	54.29	45.84	1,087.18	300.50
Price to Earnings (P/E)	0.00	29.92	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	3.34%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	10.79	3.37	13.88	6.01	18.18	19.86	47.46	43.53	1,082.15	269.97
Enterprise Value to EBITDA (EV/EBITDA)	0.00	18.01	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	18.71	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	19.17	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	63.35	9.69	0.00	0.00	0.00	123.98	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	28.01	11.95	7.50	0.00	0.00	33.10	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.21	0.32	0.29	1.64	-11.82	1.23	0.59	-5.66	-1.60	-4.85
Long-Term Debt to Equity	0.21	0.29	0.29	1.53	-11.82	1.20	0.59	-5.65	-1.57	-4.77
Financial Leverage	-1.12	-1.42	-1.90	-3.02	-19.66	-4.89	-2.36	-5.15	0.52	1.15
Leverage Ratio	1.55	1.75	2.28	3.73	33.41	8.04	3.85	13.65	-3.72	-4.27
Compound Leverage Factor	1.56	1.50	2.63	4.68	43.10	11.35	4.46	15.65	-4.15	-4.93
Debt to Total Capital	17.59%	24.05%	22.44%	62.06%	109.24%	55.06%	36.94%	121.47%	267.15%	125.95%
Short-Term Debt to Total Capital	0.00%	2.01%	0.00%	3.81%	0.00%	1.10%	0.00%	0.19%	4.36%	2.21%
Long-Term Debt to Total Capital	17.59%	22.04%	22.44%	58.24%	109.24%	53.96%	36.94%	121.27%	262.78%	123.74%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	82.41%	75.95%	77.56%	37.94%	-9.24%	44.94%	63.06%	-21.47%	-167.15%	-25.95%
Debt to EBITDA	-0.40	1.50	-0.29	-0.50	-1.35	-1.49	-0.80	-1.75	-1.23	-1.14
Net Debt to EBITDA	2.65	-6.74	2.33	1.84	1.45	3.88	2.68	0.63	0.08	0.98
Long-Term Debt to EBITDA	-0.40	1.38	-0.29	-0.47	-1.35	-1.46	-0.80	-1.75	-1.21	-1.12
Debt to NOPAT	-0.56	1.60	-0.40	-0.68	-1.87	-2.11	-1.10	-2.69	-1.78	-1.75
Net Debt to NOPAT	3.70	-7.17	3.20	2.51	2.00	5.51	3.69	0.96	0.11	1.50
Long-Term Debt to NOPAT	-0.56	1.47	-0.40	-0.64	-1.87	-2.07	-1.10	-2.69	-1.75	-1.72
Altman Z-Score	-1.24	1.51	-1.85	-3.93	-3.05	0.02	1.84	-0.07	-0.74	-1.03
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	3.57	4.77	8.45	9.36	8.98	15.20	7.45	9.40	6.12	6.17
Quick Ratio	3.52	4.70	8.32	9.05	8.85	15.02	7.28	9.25	6.00	6.08
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	11	30	25	-76	-50	33	-142	-137	-250	-100
Operating Cash Flow to CapEx	870.41%	2,366.09%	-3,536.98%	-11,567.43%	-3,471.06%	80.92%	-291.62%	-2,642.40%	-29,260.81%	-10,135.43%
Free Cash Flow to Firm to Interest Expense	41.21	11.11	1.46	-3.51	-1.83	0.87	-4.85	-2.68	-4.33	-1.16
Operating Cash Flow to Interest Expense	18.22	13.71	-5.99	-4.69	-3.32	0.23	-4.86	-5.86	-7.18	-4.58
Operating Cash Flow Less CapEx to Interest Expense	16.13	13.13	-6.16	-4.73	-3.42	-0.05	-6.53	-6.08	-7.21	-4.62
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.23	0.75	0.06	0.12	0.11	0.14	0.10	0.10	0.01	0.02
Accounts Receivable Turnover	1.23	5,911.50	23.54	18.85	7.27	11.65	2.50	3.64	10.53	2.06
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	16.92	39.50	3.71	9.30	6.95	6.25	1.63	1.23	0.10	0.27
Accounts Payable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Sales Outstanding (DSO)	297.13	0.06	15.51	19.37	50.22	31.33	145.73	100.26	34.66	177.16
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	297.13	0.06	15.51	19.37	50.22	31.33	145.73	100.26	34.66	177.16
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	-28	-40	-144	-130	-149	-249	-237	-327	-424	-699
Invested Capital Turnover	-2.93	-3.13	-0.15	-0.23	-0.19	-0.28	-0.29	-0.34	-0.02	-0.03
Increase / (Decrease) in Invested Capital	-37	-11	-104	13	-19	-99	12	-90	-98	-275
Enterprise Value (EV)	309	358	186	189	488	1,109	3,343	4,117	8,149	4,987
Market Capitalization	406	492	439	346	627	1,471	3,823	4,336	8,186	5,551
Book Value per Share	$1.77	$2.33	$2.04	$0.47	($0.19)	$1.60	$2.91	($1.14)	($3.94)	($1.15)
Tangible Book Value per Share	$1.77	$2.33	$2.04	$0.47	($0.19)	$1.60	$2.91	($1.14)	($3.94)	($1.15)
Total Capital	83	124	142	68	118	252	387	503	231	522
Total Debt	15	30	32	42	129	139	143	611	617	657
Total Long-Term Debt	15	27	32	40	129	136	143	610	607	646
Net Debt	-97	-134	-254	-156	-139	-362	-481	-219	-38	-564
Capital Expenditures (CapEx)	0.56	1.56	2.88	0.88	2.62	11	49	11	1.42	3.91
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-30	-28	-27	-11	-17	-18	-7.83	-71	-79	-136
Debt-free Net Working Capital (DFNWC)	81	128	242	188	208	446	464	712	535	940
Net Working Capital (NWC)	81	125	242	185	208	443	464	711	525	928
Net Nonoperating Expense (NNE)	11	2.23	48	44	52	62	85	162	179	214
Net Nonoperating Obligations (NNO)	-97	-134	-254	-156	-139	-362	-481	-219	-38	-564
Total Depreciation and Amortization (D&A)	0.59	0.74	1.92	-0.44	-1.29	0.64	7.17	1.10	-3.84	-23
Debt-free, Cash-free Net Working Capital to Revenue	-104.63%	-26.67%	-202.27%	-33.79%	-64.70%	-32.70%	-11.11%	-75.12%	-1,054.06%	-737.40%
Debt-free Net Working Capital to Revenue	284.24%	120.18%	1,809.18%	597.08%	773.15%	798.54%	658.56%	752.24%	7,110.93%	5,087.07%
Net Working Capital to Revenue	284.24%	117.83%	1,809.18%	588.81%	773.15%	793.55%	658.56%	751.23%	6,977.07%	5,024.72%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.97)	$0.41	($2.59)	($1.95)	($2.11)	($1.97)	($2.80)	($4.33)	($5.45)	($5.26)
Adjusted Weighted Average Basic Shares Outstanding	39.59M	39.94M	49.40M	54.89M	59.45M	71.11M	84.86M	89.83M	96.52M	111.98M
Adjusted Diluted Earnings per Share	($0.97)	$0.39	($2.59)	($1.95)	($2.11)	($1.97)	($2.80)	($4.33)	($5.45)	($5.26)
Adjusted Weighted Average Diluted Shares Outstanding	39.59M	42.56M	49.40M	54.89M	59.45M	71.11M	84.86M	89.83M	96.52M	111.98M
Adjusted Basic & Diluted Earnings per Share	($0.97)	$0.00	$0.00	($1.95)	($2.11)	($1.97)	($2.80)	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	38.81M	41.73M	54.01M	54.42M	57.58M	64.52M	76.89M	95.16M	103.00M	118.41M
Normalized Net Operating Profit after Tax (NOPAT)	-26	13	-79	-62	-69	-66	-130	-227	-347	-375
Normalized NOPAT Margin	-91.37%	12.29%	-593.79%	-197.58%	-257.58%	-117.79%	-185.18%	-239.93%	-4,612.80%	-2,031.90%
Pre Tax Income Margin	-130.86%	15.46%	-955.94%	-336.92%	-452.93%	-237.55%	-306.19%	-423.20%	-7,355.55%	-3,470.07%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-138.93	7.10	-6.52	-3.92	-3.45	-2.43	-6.35	-6.83	-8.60	-6.41
NOPAT to Interest Expense	-97.70	6.93	-4.67	-2.89	-2.53	-1.70	-4.45	-4.44	-6.02	-4.34
EBIT Less CapEx to Interest Expense	-141.02	6.52	-6.69	-3.96	-3.54	-2.71	-8.02	-7.05	-8.63	-6.46
NOPAT Less CapEx to Interest Expense	-99.80	6.35	-4.84	-2.93	-2.63	-1.99	-6.11	-4.66	-6.05	-4.38
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from Cytokinetics' official financial filings.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	-53.74%	-96.48%	301.83%	-99.03%	-84.97%	-14.56%	-81.90%	-71.28%	22.49%	912.38%
EBITDA Growth	-88.92%	-564.02%	-60.68%	-1,214.02%	7.76%	-7.88%	-2.76%	-6.85%	-39.79%	-13.81%
EBIT Growth	-82.86%	-485.28%	-54.53%	-960.05%	8.79%	-11.03%	-1.42%	-3.43%	-34.55%	-9.05%
NOPAT Growth	-56.70%	-485.28%	-59.87%	-1,022.39%	-12.75%	-0.31%	-1.42%	-6.66%	-15.16%	-9.12%
Net Income Growth	-87.04%	-349.39%	-46.78%	-549.03%	9.06%	0.35%	-3.32%	-11.41%	-24.05%	-9.59%
EPS Growth	-60.00%	-363.64%	-31.43%	-482.61%	11.18%	9.80%	3.62%	2.24%	-0.74%	8.70%
Operating Cash Flow Growth	-116.77%	-119.48%	-356.10%	-34.63%	-14.48%	24.60%	-5.91%	18.47%	-5.50%	11.44%
Free Cash Flow Firm Growth	-181.39%	102.61%	-192.17%	-569.58%	90.72%	1,102.05%	100.89%	431.65%	3,376.93%	2,009.66%
Invested Capital Growth	-8.86%	-37.82%	13.73%	-9.60%	-26.62%	-29.89%	-27.76%	-89.48%	-66.13%	-64.85%
Revenue Q/Q Growth	-97.17%	-22.19%	135.72%	-81.21%	-56.40%	342.33%	-50.06%	-70.18%	85.94%	3,555.94%
EBITDA Q/Q Growth	-1,324.91%	-1.90%	3.03%	6.67%	-0.03%	-19.18%	7.64%	2.96%	-30.86%	2.97%
EBIT Q/Q Growth	-1,063.72%	-0.38%	2.01%	7.39%	-0.14%	-22.19%	10.49%	5.56%	-30.27%	0.97%
NOPAT Q/Q Growth	-897.25%	-17.14%	2.01%	1.95%	-0.18%	-4.21%	0.93%	-3.12%	-8.17%	1.25%
Net Income Q/Q Growth	-618.01%	3.46%	4.43%	2.02%	-0.61%	-5.77%	0.92%	-5.66%	-12.02%	6.56%
EPS Q/Q Growth	-560.87%	-0.66%	9.80%	2.90%	-0.75%	-2.22%	3.62%	1.50%	-3.82%	7.35%
Operating Cash Flow Q/Q Growth	7.11%	-16.84%	-24.54%	0.39%	21.02%	23.04%	-74.92%	23.31%	-2.20%	35.40%
Free Cash Flow Firm Q/Q Growth	-516.20%	101.37%	-19,855.51%	58.29%	91.77%	277.34%	-85.34%	15,406.81%	-18.73%	14.17%
Invested Capital Q/Q Growth	-5.34%	-7.56%	1.18%	2.12%	-21.70%	-10.34%	2.80%	-45.17%	-6.70%	-9.48%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
EBITDA Margin	-5,056.58%	-6,621.87%	-2,724.08%	-13,526.64%	-31,033.86%	-8,361.36%	-15,464.43%	-50,326.10%	-35,417.06%	-939.98%
Operating Margin	-4,311.77%	-6,491.06%	-2,698.31%	-14,077.16%	-32,345.24%	-7,620.69%	-15,117.96%	-52,277.91%	-30,410.58%	-821.41%
EBIT Margin	-5,031.53%	-6,491.06%	-2,698.31%	-13,295.27%	-30,535.98%	-8,435.17%	-15,117.96%	-47,879.12%	-33,542.33%	-908.57%
Profit (Net Income) Margin	-5,658.45%	-7,019.93%	-2,846.07%	-14,837.02%	-34,238.62%	-8,187.56%	-16,244.67%	-57,557.43%	-34,674.95%	-886.28%
Tax Burden Percent	100.00%	93.18%	95.33%	100.00%	100.00%	86.59%	94.49%	99.86%	90.40%	85.05%
Interest Burden Percent	112.46%	116.07%	110.64%	111.60%	112.13%	112.10%	113.72%	120.38%	114.36%	114.69%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Equity (ROE)	-242.14%	-572.15%	764.11%	486.80%	231.64%	212.96%	169.74%	485.63%	254.64%	226.00%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	-783.64%	-661.58%	-303.06%	-170.55%	-262.73%	-69.07%	-66.82%	-130.27%	-99.21%	-15.08%
Return on Assets (ROA)	-881.28%	-715.48%	-319.65%	-190.33%	-294.59%	-67.05%	-71.79%	-156.61%	-102.56%	-14.71%
Return on Common Equity (ROCE)	-242.14%	-572.15%	764.11%	486.80%	231.64%	212.96%	169.74%	485.63%	254.64%	226.00%
Return on Equity Simple (ROE_SIMPLE)	1,765.94%	0.00%	188.11%	161.99%	120.04%	0.00%	133.94%	-502.33%	4,143.50%	0.00%
Net Operating Profit after Tax (NOPAT)	-76	-89	-87	-85	-86	-89	-88	-91	-99	-97
NOPAT Margin	-3,018.24%	-4,543.74%	-1,888.82%	-9,854.01%	-22,641.67%	-5,334.49%	-10,582.57%	-36,594.54%	-21,287.41%	-574.99%
Net Nonoperating Expense Percent (NNEP)	-16.28%	-13.85%	-15.12%	-22.59%	-37.57%	-37.18%	-86.00%	-15.13%	-21.73%	-17.51%
Return On Investment Capital (ROIC_SIMPLE)	-	-17.69%	-	-	-	-38.59%	-	-	-	-18.65%
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	1,917.38%	2,757.74%	1,076.63%	4,581.55%	10,611.38%	2,638.40%	5,449.10%	20,411.25%	12,235.85%	368.28%
R&D to Revenue	2,494.39%	3,833.32%	1,721.68%	9,595.62%	21,833.86%	5,082.30%	9,768.86%	31,966.67%	18,274.73%	553.13%
Operating Expenses to Revenue	4,411.77%	6,591.06%	2,798.31%	14,177.16%	32,445.24%	7,720.69%	15,217.96%	52,377.91%	30,510.58%	921.41%
Earnings before Interest and Taxes (EBIT)	-127	-127	-124	-115	-115	-141	-126	-119	-155	-154
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-127	-130	-126	-117	-117	-140	-129	-125	-164	-159
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	52.34	0.00	0.00
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	52.34	0.00	0.00
Price to Revenue (P/Rev)	30.77	45.84	34.15	313.48	361.88	1,087.18	1,832.23	1,812.69	1,929.92	300.50
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	28.83	43.53	33.20	315.21	368.83	1,082.15	1,827.91	1,587.05	1,735.81	269.97
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	-38.09	-5.66	-2.67	-1.83	-1.39	-1.60	-1.56	6.03	-47.16	-4.85
Long-Term Debt to Equity	-38.09	-5.65	-2.67	-1.83	-1.39	-1.57	-1.53	5.93	-46.33	-4.77
Financial Leverage	-3.50	-5.15	5.18	1.73	0.51	0.52	0.18	3.07	1.26	1.15
Leverage Ratio	8.17	13.65	-15.49	-7.00	-3.99	-3.72	-2.72	-10.26	-4.81	-4.27
Compound Leverage Factor	9.19	15.85	-17.13	-7.81	-4.48	-4.17	-3.09	-12.35	-5.50	-4.89
Debt to Total Capital	102.70%	121.47%	160.02%	220.40%	357.79%	267.15%	278.47%	85.78%	102.17%	125.95%
Short-Term Debt to Total Capital	0.00%	0.19%	0.00%	0.00%	0.00%	4.36%	5.19%	1.51%	1.79%	2.21%
Long-Term Debt to Total Capital	102.70%	121.27%	160.02%	220.40%	357.79%	262.78%	273.28%	84.27%	100.37%	123.74%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	-2.70%	-21.47%	-60.02%	-120.40%	-257.79%	-167.15%	-178.47%	14.22%	-2.17%	-25.95%
Debt to EBITDA	-2.86	-1.75	-1.54	-1.25	-1.21	-1.23	-1.23	-1.28	-1.18	-1.14
Net Debt to EBITDA	1.35	0.63	0.24	-0.04	-0.11	0.08	0.03	1.38	1.12	0.98
Long-Term Debt to EBITDA	-2.86	-1.75	-1.54	-1.25	-1.21	-1.21	-1.20	-1.26	-1.15	-1.12
Debt to NOPAT	-3.97	-2.69	-2.35	-1.81	-1.75	-1.78	-1.77	-1.85	-1.79	-1.75
Net Debt to NOPAT	1.88	0.96	0.36	-0.05	-0.16	0.11	0.05	2.00	1.70	1.50
Long-Term Debt to NOPAT	-3.97	-2.69	-2.35	-1.81	-1.75	-1.75	-1.74	-1.82	-1.76	-1.72
Altman Z-Score	1.27	0.65	-0.44	-1.31	-2.02	0.68	-0.16	0.72	0.49	-0.09
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	11.56	9.40	9.05	8.94	7.22	6.12	7.19	10.39	9.28	6.17
Quick Ratio	11.37	9.25	8.84	8.64	6.97	6.00	6.98	10.28	9.22	6.08
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-51	0.70	-138	-58	-4.75	8.43	1.24	192	156	178
Operating Cash Flow to CapEx	-1,327.44%	-3,063.65%	-30,419.40%	-16,988.15%	-43,729.55%	-96,151.95%	0.00%	-5,186.06%	-14,479.32%	-5,082.95%
Free Cash Flow to Firm to Interest Expense	-3.25	0.04	-10.46	-4.32	-0.34	0.49	0.07	7.88	6.98	7.87
Operating Cash Flow to Interest Expense	-5.33	-6.04	-9.24	-9.11	-6.87	-4.34	-7.48	-4.09	-4.55	-2.90
Operating Cash Flow Less CapEx to Interest Expense	-5.73	-6.23	-9.27	-9.17	-6.89	-4.34	-7.48	-4.17	-4.58	-2.96
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.16	0.10	0.11	0.01	0.01	0.01	0.00	0.00	0.00	0.02
Accounts Receivable Turnover	100.91	3.64	27.77	6.73	3.26	10.53	4.08	0.00	2.35	2.06
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	2.21	1.23	1.27	0.13	0.10	0.10	0.05	0.04	0.05	0.27
Accounts Payable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Sales Outstanding (DSO)	3.62	100.26	13.14	54.24	111.93	34.66	89.50	0.00	155.51	177.16
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	3.62	100.26	13.14	54.24	111.93	34.66	89.50	0.00	155.51	177.16
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	-304	-327	-323	-316	-384	-424	-412	-599	-639	-699
Invested Capital Turnover	-0.51	-0.34	-0.28	-0.03	-0.02	-0.02	-0.01	-0.01	-0.01	-0.03
Increase / (Decrease) in Invested Capital	-25	-90	51	-28	-81	-98	-90	-283	-254	-275
Enterprise Value (EV)	4,274	4,117	3,255	3,137	2,882	8,149	6,858	4,974	5,588	4,987
Market Capitalization	4,561	4,336	3,349	3,120	2,828	8,186	6,875	5,681	6,212	5,551
Book Value per Share	($0.17)	($1.14)	($2.41)	($3.48)	($4.57)	($3.94)	($3.89)	$1.04	($0.12)	($1.15)
Tangible Book Value per Share	($0.17)	($1.14)	($2.41)	($3.48)	($4.57)	($3.94)	($3.89)	$1.04	($0.12)	($1.15)
Total Capital	593	503	382	277	170	231	222	764	642	522
Total Debt	609	611	611	610	609	617	618	655	656	657
Total Long-Term Debt	609	610	611	610	609	607	607	643	644	646
Net Debt	-288	-219	-94	17	54	-38	-16	-707	-625	-564
Capital Expenditures (CapEx)	6.33	3.21	0.40	0.72	0.22	0.08	0.00	1.92	0.70	1.29
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-60	-71	-59	-45	-56	-79	-58	-80	-91	-136
Debt-free Net Working Capital (DFNWC)	808	712	605	521	484	535	561	977	920	940
Net Working Capital (NWC)	808	711	605	521	484	525	550	965	909	928
Net Nonoperating Expense (NNE)	66	48	44	43	44	48	47	52	62	53
Net Nonoperating Obligations (NNO)	-288	-219	-94	17	54	-38	-16	-707	-625	-564
Total Depreciation and Amortization (D&A)	-0.63	-2.56	-1.19	-2.01	-1.88	1.23	-2.89	-6.09	-8.68	-5.32
Debt-free, Cash-free Net Working Capital to Revenue	-40.40%	-75.12%	-59.72%	-449.80%	-710.76%	-1,054.06%	-1,534.97%	-2,559.73%	-2,838.86%	-737.40%
Debt-free Net Working Capital to Revenue	544.95%	752.24%	617.43%	5,234.71%	6,189.29%	7,110.93%	14,961.86%	31,159.96%	28,589.90%	5,087.07%
Net Working Capital to Revenue	544.95%	751.23%	617.43%	5,234.71%	6,189.29%	6,977.07%	14,654.82%	30,792.37%	28,232.03%	5,024.72%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($1.52)	($1.53)	($1.38)	($1.34)	($1.35)	($1.38)	($1.33)	($1.31)	($1.36)	($1.26)
Adjusted Weighted Average Basic Shares Outstanding	93.76M	89.83M	95.16M	95.76M	96.07M	96.52M	101.92M	109.24M	117.69M	111.98M
Adjusted Diluted Earnings per Share	($1.52)	($1.53)	($1.38)	($1.34)	($1.35)	($1.38)	($1.33)	($1.31)	($1.36)	($1.26)
Adjusted Weighted Average Diluted Shares Outstanding	93.76M	89.83M	95.16M	95.76M	96.07M	96.52M	101.92M	109.24M	117.69M	111.98M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	94.63M	95.16M	95.64M	96.00M	98.05M	103.00M	104.85M	117.66M	118.01M	118.41M
Normalized Net Operating Profit after Tax (NOPAT)	-76	-89	-87	-85	-86	-89	-88	-91	-99	-97
Normalized NOPAT Margin	-3,018.24%	-4,543.74%	-1,888.82%	-9,854.01%	-22,641.67%	-5,334.49%	-10,582.57%	-36,594.54%	-21,287.41%	-574.99%
Pre Tax Income Margin	-5,658.45%	-7,534.13%	-2,985.35%	-14,837.02%	-34,238.62%	-9,455.74%	-17,192.34%	-57,637.75%	-38,358.32%	-1,042.05%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-8.03	-7.81	-9.40	-8.62	-8.25	-8.27	-7.29	-4.91	-6.96	-6.81
NOPAT to Interest Expense	-4.81	-5.47	-6.58	-6.39	-6.12	-5.23	-5.10	-3.75	-4.42	-4.31
EBIT Less CapEx to Interest Expense	-8.43	-8.01	-9.43	-8.68	-8.26	-8.27	-7.29	-4.99	-7.00	-6.86
NOPAT Less CapEx to Interest Expense	-5.22	-5.66	-6.61	-6.45	-6.13	-5.23	-5.10	-3.83	-4.45	-4.36
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Frequently Asked Questions About Cytokinetics' Financials

When does Cytokinetics's fiscal year end?

According to the most recent income statement we have on file, Cytokinetics' financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Cytokinetics' net income changed over the last 9 years?

Cytokinetics' net income appears to be on an upward trend, with a most recent value of -$589.53 million in 2024, rising from -$37.50 million in 2015. The previous period was -$526.24 million in 2023.

What is Cytokinetics's operating income?

Cytokinetics's total operating income in 2024 was -$536.25 million, based on the following breakdown:

Total Gross Profit: $18.47 million
Total Operating Expenses: $554.72 million

How has Cytokinetics revenue changed over the last 9 years?

Over the last 9 years, Cytokinetics' total revenue changed from $28.66 million in 2015 to $18.47 million in 2024, a change of -35.5%.

How much debt does Cytokinetics have?

Cytokinetics' total liabilities were at $1.54 billion at the end of 2024, a 27.0% increase from 2023, and a 3,195.1% increase since 2015.

How much cash does Cytokinetics have?

In the past 9 years, Cytokinetics' cash and equivalents has ranged from $36.43 million in 2019 to $125.21 million in 2017, and is currently $94.86 million as of their latest financial filing in 2024.

How has Cytokinetics' book value per share changed over the last 9 years?

Over the last 9 years, Cytokinetics' book value per share changed from 1.77 in 2015 to -1.15 in 2024, a change of -165.0%.

Related Companies

This page (NASDAQ:CYTK) was last updated on 4/21/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cytokinetics (CYTK) Financials

Frequently Asked Questions About Cytokinetics' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cytokinetics (CYTK) Financials

Annual Income Statements for Cytokinetics

Quarterly Income Statements for Cytokinetics

Annual Cash Flow Statements for Cytokinetics

Quarterly Cash Flow Statements for Cytokinetics

Annual Balance Sheets for Cytokinetics

Quarterly Balance Sheets for Cytokinetics

Annual Metrics and Ratios for Cytokinetics

Quarterly Metrics and Ratios for Cytokinetics

Frequently Asked Questions About Cytokinetics' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools